BDBM517047 (S)-N-(3-fluoro-4-((3- ((1-hydroxypropan-2- yl)amino)-1H- pyrazolo[3,4-b]pyridin- 4-yl)oxy)phneyl)-1-(4- fluorophenyl)-5-methyl- 2-oxo-1,2- dihydropyridine-3- carboxamide::US11104676, Example 117::US11104676, Example 118

SMILES C[C@@H](CO)Nc1n[nH]c2nccc(Oc3ccc(NC(=O)c4cn(C)cc(-c5ccc(F)cc5)c4=O)cc3F)c12

InChI Key InChIKey=SOZIDKBTBOAWJZ-UHFFFAOYSA-N

Data  24 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 24 hits for monomerid = 517047   

TargetHepatocyte growth factor receptor [Y1230C](Human)
Array Biopharma

US Patent
LigandPNGBDBM517047((S)-N-(3-fluoro-4-((3- ((1-hydroxypropan-2- yl)ami...)
Affinity DataIC50: 1.30nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [Y1230S](Human)
Array Biopharma

US Patent
LigandPNGBDBM517047((S)-N-(3-fluoro-4-((3- ((1-hydroxypropan-2- yl)ami...)
Affinity DataIC50: 5.5nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [Y1230H](Human)
Array Biopharma

US Patent
LigandPNGBDBM517047((S)-N-(3-fluoro-4-((3- ((1-hydroxypropan-2- yl)ami...)
Affinity DataIC50: 12.4nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [Y1230C](Human)
Array Biopharma

US Patent
LigandPNGBDBM517047((S)-N-(3-fluoro-4-((3- ((1-hydroxypropan-2- yl)ami...)
Affinity DataIC50: 6.30nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [L1195V](Human)
Array Biopharma

US Patent
LigandPNGBDBM517047((S)-N-(3-fluoro-4-((3- ((1-hydroxypropan-2- yl)ami...)
Affinity DataIC50: 31nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [F1200I](Human)
Array Biopharma

US Patent
LigandPNGBDBM517047((S)-N-(3-fluoro-4-((3- ((1-hydroxypropan-2- yl)ami...)
Affinity DataIC50: 12.1nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [D1228N](Human)
Array Biopharma

US Patent
LigandPNGBDBM517047((S)-N-(3-fluoro-4-((3- ((1-hydroxypropan-2- yl)ami...)
Affinity DataIC50: 8.40nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [D1228H](Human)
Array Biopharma

US Patent
LigandPNGBDBM517047((S)-N-(3-fluoro-4-((3- ((1-hydroxypropan-2- yl)ami...)
Affinity DataIC50: 17.8nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [1-13,15-1390](Human)
Array Biopharma

US Patent
LigandPNGBDBM517047((S)-N-(3-fluoro-4-((3- ((1-hydroxypropan-2- yl)ami...)
Affinity DataIC50: 18.5nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor(Human)
Array Biopharma

US Patent
LigandPNGBDBM517047((S)-N-(3-fluoro-4-((3- ((1-hydroxypropan-2- yl)ami...)
Affinity DataIC50: 4.30nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [Y1230S](Human)
Array Biopharma

US Patent
LigandPNGBDBM517047((S)-N-(3-fluoro-4-((3- ((1-hydroxypropan-2- yl)ami...)
Affinity DataIC50: 1.30nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [Y1230H](Human)
Array Biopharma

US Patent
LigandPNGBDBM517047((S)-N-(3-fluoro-4-((3- ((1-hydroxypropan-2- yl)ami...)
Affinity DataIC50: 6.60nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Array Biopharma

US Patent
LigandPNGBDBM517047((S)-N-(3-fluoro-4-((3- ((1-hydroxypropan-2- yl)ami...)
Affinity DataIC50: 800nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [L1195V](Human)
Array Biopharma

US Patent
LigandPNGBDBM517047((S)-N-(3-fluoro-4-((3- ((1-hydroxypropan-2- yl)ami...)
Affinity DataIC50: 46.7nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [F1200I](Human)
Array Biopharma

US Patent
LigandPNGBDBM517047((S)-N-(3-fluoro-4-((3- ((1-hydroxypropan-2- yl)ami...)
Affinity DataIC50: 1.5nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [D1228N](Human)
Array Biopharma

US Patent
LigandPNGBDBM517047((S)-N-(3-fluoro-4-((3- ((1-hydroxypropan-2- yl)ami...)
Affinity DataIC50: 3.10nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [D1228H](Human)
Array Biopharma

US Patent
LigandPNGBDBM517047((S)-N-(3-fluoro-4-((3- ((1-hydroxypropan-2- yl)ami...)
Affinity DataIC50: 6.20nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor [1-13,15-1390](Human)
Array Biopharma

US Patent
LigandPNGBDBM517047((S)-N-(3-fluoro-4-((3- ((1-hydroxypropan-2- yl)ami...)
Affinity DataIC50: 3.80nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetHepatocyte growth factor receptor(Human)
Array Biopharma

US Patent
LigandPNGBDBM517047((S)-N-(3-fluoro-4-((3- ((1-hydroxypropan-2- yl)ami...)
Affinity DataIC50: 2.40nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor TYRO3(Human)
Array Biopharma

US Patent
LigandPNGBDBM517047((S)-N-(3-fluoro-4-((3- ((1-hydroxypropan-2- yl)ami...)
Affinity DataIC50: 2.62E+4nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Mer(Human)
Array Biopharma

US Patent
LigandPNGBDBM517047((S)-N-(3-fluoro-4-((3- ((1-hydroxypropan-2- yl)ami...)
Affinity DataIC50: 6.10E+3nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Array Biopharma

US Patent
LigandPNGBDBM517047((S)-N-(3-fluoro-4-((3- ((1-hydroxypropan-2- yl)ami...)
Affinity DataIC50: 1.80E+3nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor TYRO3(Human)
Array Biopharma

US Patent
LigandPNGBDBM517047((S)-N-(3-fluoro-4-((3- ((1-hydroxypropan-2- yl)ami...)
Affinity DataIC50: 1.36E+4nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Mer(Human)
Array Biopharma

US Patent
LigandPNGBDBM517047((S)-N-(3-fluoro-4-((3- ((1-hydroxypropan-2- yl)ami...)
Affinity DataIC50: 3.10E+3nMAssay Description:The affinity of compound binding to wild type and mutant human MET kinases is measured using Invitrogen's LanthaScreen Eu Kinase Binding technolo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2022
Entry Details
Go to US Patent